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Aim: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in adults
with type 2 diabetes mellitus. The aim of the present study was to test whether plasma
basic fibroblast growth factor (bFGF) levels predict future CVD occurrence in adults from
the Veterans Affairs Diabetes Trial (VADT).
Methods: Nearly 400 veterans, 40 years of age or older having a mean baseline diabetes
duration of 11.4 years were recruited from outpatient clinics at six geographically distrib-
uted sites in the VADT. Within the VADT, they were randomly assigned to intensive or
standard glycemic treatment, with follow-up as much as seven and one-half years. CVD
occurrence was examined at baseline in the patient population and during randomized
treatment. Plasma bFGF was determined with a sensitive, specific two-site enzyme-linked
immunoassay at the baseline study visit in all 399 subjects and repeated at the year 1 study
visit in a randomly selected subset of 215 subjects.
Results: One hundred and five first cardiovascular events occurred in these 399 subjects.
The best fit model of risk factors associated with the time to first CVD occurrence (in
the study) over a seven and one-half year period had as significant predictors: prior car-
diovascular event [hazard ratio (HR) 3.378; 95% confidence intervals (CI) 3.079–3.807;
P <0.0001), baseline plasma bFGF (HR 1.008; 95% CI 1.002–1.014; P =0.01), age (HR
1.027; 95% CI 1.004–1.051; P =0.019), baseline plasma triglycerides (HR 1.001; 95%
CI 1.000–1.002; P =0.02), and diabetes duration-treatment interaction (P =0.03). Inten-
sive glucose-lowering was associated with significantly decreased hazard ratios for CVD
occurrence (0.38–0.63) in patients with known diabetes duration of 0–10 years, and non-
significantly increased hazard ratios for CVD occurrence (0.82–1.78) in patients with longer
diabetes duration.
Conclusion: High level of plasma bFGF is a predictive biomarker of future CVD occurrence
in this population of adult type 2 diabetes.
Keywords: basic fibroblast growth factor, type 2 diabetes mellitus, cardiovascular disease
INTRODUCTION
Intensive diabetes treatment slows the development of retinopa-
thy, nephropathy, and neuropathy (1); however, its role in reducing
cardiovascular disease (CVD) events in adult type 2 diabetes is
more complex. Evidence from the United Kingdom Prospective
Diabetes Study (UKPDS) follow-up study indicated a “delayed”
beneficial cardiovascular effect from intensive glucose-lowering in
newly diagnosed type 2 diabetes (2). Among more advanced type
2 diabetic subjects from the ACCORD, ADVANCE, and veterans
affairs diabetes trial (VADT), however, intensive glucose-lowering
either did not show a beneficial effect on lowering the rate of
cardiovascular events (3) or it increased cardiovascular mortality
(i.e., in ACCORD) (4).
Biomarkers that can predict an increased risk for CVD occur-
rence in a category of adult diabetic patients undergoing sub-
stantial treatment intensification would be valuable for guiding
patient regarding treatment selection. Basic fibroblast growth fac-
tor (bFGF) is a potent angiogenic and smooth muscle cell mitogen
which increases in subsets of advanced adult type 2 diabetes having
micro-(albuminuria) (5) and/or abdominal obesity (i.e., increased
waist/hip ratio) (6). In a planned secondary analysis to the VADT
(n= 399), we reported that baseline plasma bFGF was a novel
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significant predictor of the time to first post-baseline occurrence
of coronary heart disease (CHD) (7). The aims of the present
analysis were (1) to test whether baseline plasma bFGF predicts
the time to first post-baseline CVD occurrence in risk models
that adjust for treatment-duration interaction, (2) to determine
whether elevated bFGF at year 1 of treatment predicts the subse-
quent occurrence of CVD events in the VADT subjects, and (3)
to investigate novel mechanisms for vascular cell growth promo-
tion involving bFGF or long-lasting (FGF-like) autoantibodies in
diabetic subsets having increased plasma bFGF.
SUBJECTS AND METHODS
STUDY SUBJECTS
The study design of the VADT has been previously reported (8).
Patients with renal insufficiency or congestive heart failure were
excluded from participation. Baseline insulin use (yes/no), and
occurrence of a macrovascular event prior to baseline (yes/no)
were stratification variables jointly used when subjects were ran-
domized at each participating VA site. CVD occurrences encom-
passing ischemic coronary artery disease, congestive heart fail-
ure, cerebrovascular disease, and peripheral arterial disease events
comprised the pre-specified endpoint of the main VADT study.
Informed consent for the Investigational Review Board-approved
substudy was obtained from 399 diabetic subjects who had con-
sented to participate in the main VADT at six outpatient sites. As
previously described (7), aliquots of EDTA plasma obtained in the
morning from fasting subjects were shipped frozen (dry ice) to
a central laboratory [Maverick, Boston Veterans Affairs Medical
Center (VAMC), Boston, MA, USA] where they were inventoried
and stored at −80°C. Archived, coded frozen EDTA plasma from
consecutively enrolled patients was shipped to the laboratory of
Dr. Zimering [VA New Jersey Health Care System, Lyons, NJ, USA
(VANJ)] where basic fibroblast growth factor immunoreactivity
(bFGF-IR) assays were performed. All other assays were performed
in the Central Laboratory of the VADT (Tufts University, Boston,
MA, USA).
The baseline and follow-up (year 3) clinical characteristics in
the study subjects are shown in Table 1.
PATIENT SUBGROUPS
I. A convenience sample consisting of a first group of 26 plasma
specimens was used to test for a correlation between plasma
bFGF-IR and endothelial cell growth activity (Figure 2). The 26
subjects in this subgroup were consecutively enrolled subjects
from three study sites.
Table 1 | Comparison of baseline and follow-up characteristics for Standard and Intensive treatment groups comprising 399 substudy patients.
Variable Baseline Follow-upa
STD INT P -value STD INT P -value
(N =200) (N =199) (N =200) (N =199)
Age (years) 58.6 60.1 0.08
Diabetes duration (years) 10.3 12.4 0.007
Baseline insulin 47% 48% 0.80
Male 97% 96% 0.99
Prior CV event 38% 37% 0.79
Hypertension 73% 68% 0.26
Race
Non-hispanic white 58% 56% 0.73
African-American 21% 22% 0.79
Hispanic 17% 19% 0.68
Current smoking 16% 20% 0.35 11% 13% 0.43
bFGF (pg/mL) 16.0 14.2 0.50 8.1b 8.0b 0.95b
HbA1C (%) 9.6 9.4 0.37 8.8 7.2 <0.0001
Systolic bp (mm Hg) 130.3 131.5 0.51 128.2 124.5 0.03
BMI (kg/m2) 31.0 31.0 0.97 31.6 32.5 0.11
Weight (lbs) 212.6 213.2 0.88 216.4 224.3 0.06
Waist/hip ratio 0.99 0.99 0.87 1.00 0.99 0.24
Total chol (mg/dL) 183.2 182.6 0.90 163.4 155.7 0.03
LDL chol (mg/dL) 107.1 107.2 0.96 90.4 86.5 0.21
HDL chol (mg/dL) 36.4 37.6 0.25 38.9 40.1 0.32
Triglycerides (mg/dL) 208.7 184.1 0.16 177.8 148.5 0.006
Serum creat (mg/dL) 1.00 0.99 0.67 1.17 1.15 0.73
Results are means or percentages, and P-values are obtained from the comparison of the two treatment groups.
aYear 3 or previous non-missing value prior to year 3.
bYear 1 annual visit.
Chol, cholesterol; creat, creatinine.
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II. A convenience sample consisting of a second group of 27 plasma
specimens was used to test for an association between plasma
bFGF-IR and growth stimulatory activity in protein A eluates.
The 27 subjects were consecutively enrolled from three study
sites.
MEDICATIONS
Baseline anti-diabetic medications included oral agents and/or
insulin, as previously reported (9). Similar classes of anti-diabetic
medications were used in patients randomized to the standard or
intensive glycemic treatment groups, but at different doses. Sub-
stantial proportions of patients were treated with one or more
anti-hypertensive medications including angiotensin converting
enzyme inhibitors (67%) or angiotensin receptor blockers (7%).
Sixty-two percent of patients reported use of a statin at baseline,
and 13% of patients reported baseline use of a fibrate medication.
STUDY OUTCOMES
As previously reported (7), CVD was adjudicated by an indepen-
dent Study Endpoints Committee. The subset of CVD outcomes
comprising CHD is defined as myocardial infarction, coronary
revascularization, inoperable coronary artery disease, or cardio-
vascular death. Baseline plasma bFGF-IR was determined in
(n= 399) subjects and at 1 year post-baseline, a bFGF-IR deter-
mination was done due to budgetary constraints in a randomly
selected subset of 215 subjects. Data on plasma bFGF-IR was
obtained without information about study endpoint occurrence.
We separately modeled the association of risk factors with time to
first post-baseline cardiovascular (CVD) or to first post-baseline
CHD in the 399 subjects for whom such post-randomization data
was available.
LABORATORY AND CLINICAL MEASURES
Routine laboratory measures were determined by standardized
direct enzymatic assay methods (9). The analyzed blood pressure
(BP) was the median value of three consecutive determinations
recorded from subjects that had been seated and resting for 5-min.
PLASMA SAMPLES
Basic fibroblast growth factor assays
The determination and stability of basic FGF immunoreactivity
(bFGF-IR) in plasma has been previously described (7, 10). Plasma
bFGF-IR ranged between 0 and 4 pg/mL in healthy male volun-
teer blood donors, and there was no effect of age on plasma bFGF
level (11).
Cell culture and growth assays
Bovine pulmonary artery (BPA) endothelial cells (Clonetics Inc.,
San Diego, CA, USA) were cultured under previously described
conditions (12). Growth-promoting activity is expressed as a per-
centage of the control cell number (after 4 days incubation in the
presence of test fractions) for cells grown in EGM/M199 with 10%
FCS without added test fractions. Each point represents the mean
of 4–6 determinations. The intra- and inter-assay coefficients of
variation were 4 and 7% at 1:50 dilution of protein-A-eluted frac-
tions from plasma of three diabetic subjects (n= 3 assays in each
patient).
Protein A affinity chromatography
Protein A chromatography was carried out as previously described
(12). Eluate fractions were stored at 0–4°C. All fractions were ster-
ile filtered (Millipore Corp., Bedford, MA, USA; 0.22µm) before
assay for growth-promoting activity.
Chemicals
Recombinant human bFGF was from Austral Biologicals Inc.
(San Ramona, CA, USA). All other chemicals and reagents were
analytical grade.
Protein determinations
Protein concentrations were determined by a bicinchoninic acid
protein assay kit (Pierce Chemical Co., Rockford, IL, USA).
Statistics
The VADT was conducted using the intention-to-treat principle
(9). As previously reported (7), baseline insulin use and base-
line cardiovascular event-history (the randomization stratification
variables) and glycemic treatment group were included as covari-
ates in models when testing for a bFGF effect on CVD occur-
rence. Cox proportional hazards regression analysis was used to
model the association between baseline risk factors and time to
first post-baseline CHD, or CVD occurrence. Backward elimi-
nation was used to obtain the best fit model using P ≤ 0.05 as
the cutoff for variable retention in the final model. From our
prior work (5), we hypothesized that increased, post-treatment
bFGF (determined at year 1) may reflect suboptimal blockade
of the renin-angiotensin system which is a known risk factor for
occurrence of CVD events (13). Consistent with our prior method-
ology (14), year 1 bFGF, when used in models of the risk factors
associated with time to first post-year 1 CVD occurrence, was
dichotomized at the upper limit of normal reported in adult men
(4.4 pg/mL) (11).
RESULTS
BASELINE AND FOLLOW-UP CHARACTERISTICS IN THE STUDY
PATIENTS
Our subject group was comprised of men having the following
means: age: 59 years; diabetes duration: 11.4 years; hemoglobin
A1c: 9.5%; BMI: 31 kg/m2; and 37% reported a prior macrovascu-
lar event at study entry (Table 1). Baseline clinical characteristics
were similar in subjects randomized to standard and intensive
treatment, with the exception of mean diabetes duration, which
was significantly longer (12.4 vs. 10.3 years) for intensively treated
patients (Table 1). At the year 3 study visit, intensive treatment was
associated with significantly lower mean glycosylated hemoglobin,
systolic BP, plasma total cholesterol, and triglyceride concentra-
tions (Table 1). Mean body weight, BMI, plasma HDL cholesterol,
and creatinine concentration increased significantly in all subjects
after 3 years’ treatment (data not shown), but the mean values
did not differ significantly when comparing standard to intensive
treatment patients (Table 1).
FREQUENCY OF OCCURRENCE OF POOLED END POINTS
One hundred and five first CVD events occurred in 105 patients
during an average of 6 years of VADT study treatment including
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57 primary CVD events in the Standard treatment group and 48
primary CVD events in the Intensive treatment group (data not
shown).
ASSOCIATION BETWEEN PLASMA bFGF AND FIRST POST-BASELINE
OCCURRENCE OF CVD
The best-fitting model of risk factors associated with the time
to first post-randomization occurrence of the main study CVD
endpoint (n= 105 events in 399 subjects) had as significant pre-
dictors: prior CV event [hazard ratio (HR) 3.378; 95% confi-
dence intervals (CI) 3.079–3.807; P < 0.0001], age (HR 1.027;
95% CI 1.004–1.051; P = 0.019), baseline bFGF (HR 1.008; 95%
CI 1.002–1.014; P = 0.013), baseline triglycerides (HR 1.001; 95%
CI 1.000–1.002; P = 0.015), and duration× treatment interaction
(P = 0.033) (Table 2). There was no significant association of base-
line use of a statin, either ACEi or ARB, or fibrate medication with
time to first post-baseline CVD occurrence. There was no signifi-
cant association of time to first post-baseline CVD occurrence and
baseline triglyceride× treatment× duration (P = 0.759), baseline
triglyceride× treatment (P = 0.845) or baseline HDL cholesterol
concentration (P = 0.441). The (treatment× duration) adjusted
model predicted a significantly decreased CVD HR- (CI= 0.38–
0.63) associated with intensive glucose-lowering among patients
with 10 or fewer years of baseline known diabetes dura-
tion, and a non-significant HR (CI= 0.82–1.78) for sub-
jects with a baseline diabetes duration of 15 years or longer
(Figure 1).
RISK FACTORS ASSOCIATED WITH ONGOING CVD OCCURRENCE IN
ADVANCED DIABETES
As previously reported (7), mean plasma bFGF at year 1 decreased
significantly compared to baseline levels,but did not differ between
STD and INT patients (8.1 vs. 8.0 pg/mL) (Table 1). Of the orig-
inal 399 study subjects, we were able to obtain repeat plasma
bFGF at year 1 in 215 randomly selected patients who did not
differ in their mean baseline characteristics from all 399 subjects.
Secondary analyses suggests that for patients having the longest
baseline duration of diabetes (≥15 years), patient age (HR 1.052;
95% CI 1.006–1.098; P = 0.0316) is an important predictor of time
to first post-year 1 CVD occurrence (22 events in 71 patients).
Excluding age from our model, increased year 1 plasma bFGF
(>4 pg/mL) appeared to be a nearly significant predictor (HR
2.439; 95% CI 1.522–3.356; P = 0.0518) of time to first post-year
1 CVD occurrence (22 events in 71 patients) among patients with
baseline diabetes duration ≥15 years.
INCREASED BIOACTIVITY IN VADT PLASMA HAVING ELEVATED bFGF
Since basic FGF is a potent endothelial and smooth muscle cell
mitogen which may contribute to cell proliferation associated with
atherosclerosis, we compared endothelial cell bioactivity in plasma
from VADT subjects having low vs. elevated (>4 pg/mL) plasma
bFGF. Mean activity in the 25–75% ammonium sulfate pellet
fraction of plasma (127± 10%) from 14, consecutively enrolled
VADT subjects with elevated bFGF-IR (>4 pg/mL) significantly
exceeded mean activity (113± 10%) in 12 consecutively enrolled
VADT subjects with normal bFGF-IR (0–4 pg/mL, P = 0.003)
(Figure 2).
Table 2 | Cox proportional hazard ratio: time to first post-baseline CVD
event.
Variable HR 95% CI P -value
Baseline bFGF 1.008 1.002–1.014 0.0126
Prior CV event 3.378 3.079–3.807 <0.0001
Age 1.027 1.004–1.051 0.0188
Triglyceride 1.001 1.000–1.002 0.0153
Intensive treatment
5 years diabetes duration 0.489 0.275–0.869
25 years diabetes duration 1.370 0.712–2.637
n=399 subjects; HR, hazard ratio; CI, confidence interval.
FIGURE 1 | Hazard ratio for post-baseline (A) CVD or (B) CHD
occurrence in intensive treatment group by duration of diabetes
known at baseline. Squares indicate point estimates and bars denote 95%
confidence intervals. Point estimates are obtained from the multivariable
adjusted model that includes age, prior CV event, baseline bFGF, treatment,
duration, and treatment×duration and are illustrated for 5-year intervals
between 0–30 years of baseline diabetes duration.
Basic FGF lacks an amino terminal signal sequence (15),
and is sequestered in cells (16). Yet in subsets of endocrine
tumor patients having elevated plasma bFGF, we have reported
the occurrence of long-lasting, highly potent FGF-like autoanti-
bodies (12, 17). In the present study, we examined the protein
A eluates from 27 consecutively enrolled VADT subjects hav-
ing plasma bFGF-IR ranging from 0 to 29 pg/mL for proper-
ties resembling autoantibodies. In 16 of 27 subjects, endothelial
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FIGURE 2 | Endothelial cell bioactivity in the 25–75% ammonium
sulfate pellet of plasma. Ammonium sulfate pellet fractions from plasma
in 26 consecutively enrolled VADT subjects were tested for endothelial cell
growth promotion after 4 days of incubation as described in Materials and
Methods. Each point represents the mean of four–six determinations.
cell bioactivity in the protein A eluate fraction was stimulatory,
and there was a significant correlation (R= 0.81; P = 0.0002)
between plasma bFGF level and the level of growth stim-
ulatory activity in the protein A eluate fraction of plasma
(Figure 3).
DISCUSSION
The current findings suggest that baseline plasma bFGF may be a
novel significant predictor of CVD occurrence in a subset of obese,
adult male veterans with type 2 diabetes. Following adjustment
for a significant treatment− duration interaction, and baseline
plasma triglycerides, baseline plasma bFGF was still a significant
predictor of the time to first post-baseline CVD occurrence in 399
VADT subjects. This is the first evidence that plasma bFGF is a
novel candidate marker of CVD risk in a subset of obese advanced
type 2 diabetes.
Plasma basic FGF is low or undetectable in healthy subjects
(11), but increases in micro-albuminuric adult type 2 DM (5) or
in the presence of coronary artery disease (18). Growth stimu-
latory activity in the 25–75% ammonium sulfate pellet fraction
in VADT plasma having elevated bFGF may be due (in part) to
bFGF, or autoantibodies which can bind bFGF or mimic bFGF’s
growth activity. In support of the latter two possibilities, our
preliminary experiments indicated that even low concentrations
(1–2µg/mL) of protein A eluates from subsets of advanced adult
type 1 autoimmune diabetes (n= 2) or advanced adult type 2
DM having chronic kidney disease (n= 3) could be completely
neutralized by co-incubating endothelial cells with specific anti-
bFGF antibodies. This result suggests that some of the stim-
ulatory activity in protein A eluates from plasma of advanced
diabetes subjects may be FGF-like or due to an IgG which can
mimic FGF.
FIGURE 3 | Endothelial cell stimulatory activity in protein A eluate
fractions in 16 VADT plasmas was significantly correlated with
increasing plasma bFGF-IR concentration. Growth activity was
determined after 4 days’ incubation as described in Materials and Methods.
Each point represents the mean of quadruplicate determinations.
Although the tissue sources of increased plasma bFGF in obese
subjects with type 2 diabetes are not known, increased waist-
hip ratio was significantly associated with substantially increased
plasma bFGF in the VADT substudy (6). Angiotensin II stim-
ulates the release of visceral adipocytokines (TNF-alpha, IL-1,
IF-gamma) which then act to induce endothelial cell release of
bFGF (19). IF-gamma activates macrophage phagocytic function,
and promotes B cell isotype switching to the synthesis of IgG
(20). Thus the known pro-immune effects from renin-angiotensin
system (RAS) activation may act to alter long-lasting IgG autoan-
tibodies to circulating forms of bFGF in diabetic subsets (e.g.,
VADT) having substantially increased plasma bFGF. Weight gain
and/or salt and water retention frequently accompany glycemic
treatment intensification, and the latter has been reported to
enhance the expression of angiotensin II receptors in rats (21).
The current finding of a significant association between baseline
bFGF level and increased CVD risk may reflect underlying role(s)
for angiotensin II in promoting vascular hypertrophy, athero-
sclerosis, and immune interactions involving high plasma bFGF.
Our preliminary findings of significant or nearly significant asso-
ciations between advanced age or increased (>4 pg/mL) year 1
plasma bFGF, respectively and the ongoing risk for CVD occur-
rence in patients having longer-duration of diabetes (≥15 years)
are hypothesis-generating and may warrant further investigation.
These results are consistent with known RAS activation in older
subjects or in those having year 1 plasma bFGF >4 pg/mL (5).
Older patients with type 1 diabetes were more likely to experi-
ence adverse hemodynamic responses to RAS activation than their
younger counterparts (22).
Increased affinity of the FGF-like plasma autoantibodies in dia-
betic subjects for hydroxyapatite (our preliminary results) suggests
that the autoantibodies may localize to calcified areas in advanced
coronary atherosclerotic plaque and also may promote the local
cellular proliferation typically found with atherosclerosis. Inten-
sive glycemic control may have been associated with a lower rate of
CVD occurrences in our subgroup of recent-onset type 2 diabetes
by decreasing the occurrence of microvascular damage leading
to the increase of bFGF (23). Findings in the VADT substudy of
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Reaven et al. (24, 25), namely, that intensive control lowered the
subsequent risk of CVD occurrences in subjects having lower base-
line coronary calcium, and that albuminuria was a risk factor for
progression of coronary calcium, are consistent with the possi-
bility of synergistic interactions between coronary calcium and
hydroxyapatite-avid, growth-stimulating autoantibodies.
Atherogenic dyslipidemia has been associated with increased
residual cardiovascular risk in obese subjects with type 2 dia-
betes (26). Consistent with results in the main VADT (9), our
substudy group had substantially increased mean baseline plasma
triglycerides which remained elevated despite substantial glycemic
improvement (Table 1). Our multivariable risk model predicts
that each 50 mg/dL increase in baseline plasma triglycerides is
associated with a 5% increase in the hazard rate for CVD occur-
rence. The HR associated with increased bFGF (HR 1.008; 95%
CI 1.002–1.014) was only modestly increased, but is likely to be
significant for the 20% of VADT subjects who had baseline plasma
bFGF >20 pg/mL. Patients having an elevation in plasma bFGF
of 20 pg/mL compared to control patients would experience 1.17
times the hazard rate for CVD occurrence. The smaller subgroup
of patients (6%) having an elevation in bFGF of 50 pg/mL would
experience 1.5 times the hazard rate for CVD occurrence compared
to control patients with non-elevated bFGF. Taken together with
our prior finding of a significant association between markedly
increased plasma bFGF (>20 pg/mL) and increased plasma plas-
minogen activator inhibitor-1 level (6), the current results suggests
effects of bFGF on endothelial cells (i.e., proliferation, elaboration
of PAI-1) or smooth muscle cells which may contribute to clini-
cally significant increases in CHD or CVD risk in a subset of obese,
advanced type 2 DM.
“Vascular metabolic memory” refers to the association between
improved glycemic control in adult type 1 diabetes and a sub-
stantially reduced risk for later CVD occurrence (27). Since long-
standing poor glycemic control has been significantly associated
with increased FGF-like plasma bioactivity in adult type 2 DM (5),
vascular injury leading to increased plasma bFGF (23) may be one
of the unknown mechanisms underlying an association between
prior glycemia and future CVD risk.
A limitation of our study is that the results are based on mod-
erate to small sizes and may only reflect the experience of middle-
aged and older obese men with treatment-resistant diabetes. The
present findings need to be confirmed in other populations with
type 2 diabetes. Our finding of a significant treatment x duration
interaction effect on the risk for CVD occurrence in adult type 2
diabetes is consistent with results from the main VADT (28), but
needs to be interpreted cautiously since it was based on post hoc
analysis in an embedded subgroup of the main VADT.
In conclusion, the present findings suggest that baseline plasma
bFGF may be a marker of CVD risk in adult male veterans with
type 2 diabetes. These results suggest that increased plasma bFGF
may drive cell proliferation and be involved in the mechanism for
increased CVD occurrence in older adults with advanced type 2
diabetes mellitus.
ACKNOWLEDGMENTS
Supported by a grant from the Veterans Biomedical Research Insti-
tute, East Orange, NJ, USA to Mark B. Zimering; and (in part)
by the Cooperative Studies Program of the Department of Vet-
erans Affairs, Office of Research and Development, Washington,
DC, USA.
REFERENCES
1. The Diabetes Control and Complications Trial Research Group. The effect of
intensive treatment of diabetes on the development and progression of long-
term complications in insulin-dependent diabetes mellitus. N Engl J Med (1993)
329:683–9.
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of
intensive glucose control in type 2 diabetes. N Engl J Med (2008) 359:1577–89.
doi:10.1056/NEJMoa0806470
3. Control Group, Turnbull FM,Abraira C,Anderson RJ, Byington RP, Chalmers JP,
et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes.
Diabetologia (2009) 52(11):2288–98. doi:10.1007/s00125-009-1470-0
4. The Accord Study Group. Effects of intensive glucose lowering in type 2 diabetes.
N Engl J Med (2008) 358:2545–59. doi:10.1056/NEJMoa0802743
5. Zimering MB, Eng J. Increased basic fibroblast growth factor-like substance in
plasma from a subset of middle-aged or elderly male diabetic patients with
microalbuminuria or proteinuria. J Clin Endocrinol Metab (1996) 81:4446–52.
doi:10.1210/jc.81.12.4446
6. Zimering MB, Anderson RJ, Lou P, Moritz TE; Investigators for the VADT.
Plasma basic fibroblast growth factor is correlated with plasminogen activa-
tor inhibitor-1 concentration in adults from the veterans affairs diabetes trial.
Metabolism (2008) 57:1563–9. doi:10.1016/j.metabol.2008.06.012
7. Zimering MB, Anderson RJ, Ge L, Moritz TE; VADT Investigators. Increased
plasma basic fibroblast growth factor is associated with coronary heart disease
in adult type 2 diabetes. Metabolism (2011) 60:284–91. doi:10.1016/j.metabol.
2010.02.003
8. Abraira C, Duckworth W, McCarren M, Emanuele N, Arca D, Reda D, et al.
Design of the cooperative study of glycemic control and complications in dia-
betes mellitus type 2. J Diabetes Complications (2003) 17:314–22. doi:10.1016/
S1056-8727(02)00277-5
9. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glu-
cose control and vascular complications in veterans with type 2 diabetes. N Engl
J Med (2009) 360(2):129–39. doi:10.1056/NEJMoa0808431
10. Zimering MB. Effect of intravenous bisphosphonates on release of basic fibrob-
last growth factor in serum of patients with cancer-associated hypercalcemia.
Life Sci (2002) 70:1–14. doi:10.1016/S0024-3205(01)01548-X
11. Larsson A, Skoldenberg E, Ericson H. Serum and plasma levels of FGF-2 and
VEGF in healthy blood donors. Angiogenesis (2002) 5:107–10. doi:10.1023/A:
1021588227705
12. Zimering MB, Thakker-Varia S. Increased fibroblast growth factor-like autoanti-
bodies in serum from a subset of patients with cancer-associated hypercalcemia.
Life Sci (2002) 71(25):2939–59. doi:10.1016/S0024-3205(02)02160-4
13. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system
and cardiovascular risk. Lancet (2007) 369(9568):1208–19. doi:10.1016/S0140-
6736(07)60242-6
14. Zimering MB, Anderson RJ, Moritz TE, Ge L; VADT Investigators. Low plasma
basic fibroblast growth factor is associated with laser photocoagulation in
adults from the veterans affairs diabetes trial. Metabolism (2009) 58(3):393–400.
doi:10.1016/j.metabol.2008.10.014
15. Esch F, Baird A, Ling N, Ueno N, Hill F, Denoroy L, et al. Primary structure of
bovine pituitary basic fibroblast growth factor (FGF) and comparison with the
amino-terminal sequence of bovine brain acidic FGF. Proc Natl Acad Sci U S A
(1985) 19:6507–11. doi:10.1073/pnas.82.19.6507
16. Vlodavsky I, Bar-Shavit R, Ishai-Michaeli R, Bashkin P, Fuks Z. Extracel-
lular sequestration and release of fibroblast growth factor: a regulatory
mechanism? Trends Biochem Sci (1991) 16(7):268–71. doi:10.1016/0968-
0004(91)90102-2
17. Zimering MB, Riley DJ, Thakker-Varia S, Walker AM, Lakshminaryan V, Shah
R, et al. Circulating fibroblast growth factor-like autoantibodies in two patients
with multiple endocrine neoplasia type 1 and prolactinoma. J Clin Endocrinol
Metab (1994) 79:1546–52. doi:10.1210/jc.79.6.1546
18. Katinioti AA, Tousoulis D, Economou E, Stefanadis C, Trikas A, Tentolouris
C, et al. Basic fibroblast growth factor changes in response to coronary angio-
plasty in patients with stable angina. Int J Cardiol (2002) 84(2–3):195–9.
doi:10.1016/S0167-5273(02)00153-5
Frontiers in Endocrinology | Diabetes November 2013 | Volume 4 | Article 183 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zimering et al. bFGF predicts CVD in diabetes
19. Samaniego F, Markham PD, Gendelman R, Gallo RC, Ensoli B. Inflammatory
cytokines induce endothelial cells to produce and release basic fibroblast growth
factor and to promote Kaposi’s sarcoma-like lesions in nude mice. J Immunol
(1997) 158(4):1887–94.
20. Weidanz JA, Jacobson LM, Muehrer RJ, Djamali A, Hullett DA, Sprague J,
et al. ATR blockade reduces IFN-gamma production in lymphocytes in vivo
and in vitro. Kidney Int (2005) 67(6):2134–42. doi:10.1111/j.1523-1755.2005.
00318.x
21. Nickenig G, Strehlow K, Roeling J, Zolk O, Knorr A, Böhm M. Salt induces
vascular AT1 receptor overexpression in vitro and in vivo. Hypertension (1998)
31:1272–7. doi:10.1161/01.HYP.31.6.1272
22. Cherney DZ, Reich HN, Miller JA, Lai V, Zinman B, Dekker MG, et al. Age
is a determinant of acute hemodynamic responses to hyperglycemia and
angiotensin II in humans with uncomplicated type 1 diabetes mellitus.
Am J Physiol Regul Integr Comp Physiol (2010) 299(1):R206–14. doi:10.1152/
ajpregu.00027.2010
23. Gajdusek CM, Carbon S. Injury-induced release of basic fibroblast growth
factor from bovine aortic endothelium. J Cell Physiol (1989) 139:570–9.
doi:10.1002/jcp.1041390317
24. Saremi A, Moritz TE, Anderson RJ, Abraira C, Duckworth WC, Reaven PD.
Rates and determinants of coronary and abdominal aortic artery calcium pro-
gression in the veterans affairs diabetes trial (VADT). Diabetes Care (2010)
33(12):2642–7. doi:10.2337/dc10-1388
25. Reaven PD, Moritz TE, Schwenke DC, Anderson RJ, Criqui M, Detrano R, et al.
Intensive glucose-lowering therapy reduces cardiovascular disease events in vet-
erans affairs diabetes trial participants with lower calcified coronary atheroscle-
rosis. Diabetes (2009) 58(11):2642–8. doi:10.2337/db09-0618
26. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, et al.
Reduction of low-density lipoprotein cholesterol in patients with coronary heart
disease and metabolic syndrome: analysis of the Treating to New Targets study.
Lancet (2006) 368(9539):919–28. doi:10.1016/S0140-6736(06)69292-1
27. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al.
Intensive diabetes treatment and cardiovascular disease in patients with type 1
diabetes. N Engl J Med (2005) 353(25):2643–53. doi:10.1056/NEJMoa052187
28. Duckworth WC, Abraira C, Moritz TE, Davis SN, Emanuele N, Goldman S, et al.
The duration of diabetes affects the response to intensive glucose control in type
2 subjects: the VA diabetes trial. J Diabetes Complications (2011) 25(6):355–61.
doi:10.1016/j.jdiacomp.2011.10.003
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 18 September 2013; accepted: 09 November 2013; published online: 22
November 2013.
Citation: Zimering MB, Anderson RJ, Ge L, Moritz TE, Duckworth WC and Investiga-
tors for the VADT (2013) Basic fibroblast growth factor predicts cardiovascular disease
occurrence in participants from the veterans affairs diabetes trial. Front. Endocrinol.
4:183. doi:10.3389/ fendo.2013.00183
This article was submitted to Diabetes, a section of the journal Frontiers in
Endocrinology.
Copyright © 2013 Zimering, Anderson, Ge, Moritz, Duckworth and Investigators for
the VADT. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) or licensor are credited and that
the original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply with
these terms.
www.frontiersin.org November 2013 | Volume 4 | Article 183 | 7
